has any of the holders done an updated valuation
Market Opportunity Formulas 2025 2026 2027 1 Market Cap Given ( value escalated at 3% annually) AUD 1,814,983,000 AUD 1,869,432,490 AUD 1,925,515,465 2 Share Outstanding Given 127,815,700 127,815,700 127,815,700 3 Share Price GIven 13.23 AUD 14.63 AUD 15.06 4 Cash in Hand (A$359.4 million pro-forma including Q1 2025 receipts - Q4 2024 tax) AUD 359,400,000 5 Expected Cash ( R&D) Reported 6 Debt Reported AUD 0.00 7 Enterprise Value (EV) Market Cap - Cash + Debt AUD 1,455,583,000 8 TAM Product 1 DAYBUE™ (trofinetide) 9 TAM Product 2 NNZ-2591, Phelan-McDermid 10 TAM Product 3 NNZ-2591, Pitt-Hopkins 11 Target Patient Population Product 1 12 Target Patient Population Product 2 13 Target Patient Population Product 3 14 Price per patient Product 1 AUD 375,000 15 Price per patient Product 2 16 Price per patient Product 3 17 Penetration Rate Product 1 Assumption 18 Penetration Rate Product 2 Assumption 19 Penetration Rate Product 3 Assumption 20 Covered Population Product 1 Target Pop. × Penetration Rate 21 Covered Population Product2 Target Pop. × Penetration Rate 22 Covered Population Product3 23 Revenue (Actual & Projections) 24 Revenue Guidance 25 Actual Revenue Product 1 incl. 62,000,000 + Milestone Income 80,500,000+ 76,500,000 AUD 348,400,000.00 26 Actual Revenue Product 2 27 Actual Revenue Product 3 28 Actual Revenue Combined 29 Potential Annual Revenue Product 1 Covered Pop. × Pricing Per Patient AUD 0 30 Potential Annual Revenue Product 2 Covered Pop. × Pricing Per Patient 31 Potential Annual Revenue Product 3 32 Potential Annual Revenue Combined
keen to seek some feeback. they said US: 5,500 to 5,800 diagnosed Rett patients.70% of this diagnosed population has yet to try DAYBUE (from the document)Canada: 600 to 900 diagnosed Rett patients (from the document)Europe: Estimate the number of diagnosed Rett patients in the EU. You would need to find prevalence data for Rett syndrome in Europe.Japan: Estimate the number of diagnosed Rett patients in Japan.
i am assuming 350K-400K per patient treatement
- Forums
- ASX - By Stock
- NEU is materially undervalued
NEU
neuren pharmaceuticals limited
Add to My Watchlist
2.28%
!
$12.54

has any of the holders done an updated valuation Market...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.54 |
Change
0.280(2.28%) |
Mkt cap ! $1.559B |
Open | High | Low | Value | Volume |
$12.52 | $12.73 | $12.26 | $8.152M | 652.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 665 | $12.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.55 | 235 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 665 | 12.500 |
1 | 1537 | 12.470 |
1 | 1537 | 12.450 |
2 | 2037 | 12.420 |
1 | 42 | 12.400 |
Price($) | Vol. | No. |
---|---|---|
12.600 | 899 | 1 |
12.690 | 1537 | 1 |
12.720 | 2537 | 2 |
12.730 | 1010 | 1 |
12.750 | 1537 | 1 |
Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |